Tonix Pharmaceuticals.
commercial pharmaceutical company
- Reports this week
- 2
- Active events
- 1
- Connections
- 32
What's happening
Active this week
Earlier this month
-
Max Baucus highlighted biotech community growth while Tonix Pharmaceuticals CEO Seth Lederman discussed plans for a new facility in Ravalli County, Montana.Some support1 report
-
Tonix Pharmaceuticals CEO Seth Lederman purchased company stock in an insider transaction, while analyst coverage influences stock rating.Some support1 report
One to three months ago
Gone quiet
No new reports in 90+ days-
Tonix Medicines, Inc. became a commercial subsidiary of Tonix Pharmaceuticals on July 21, 2025.Some support1 report
-
Tonix Pharmaceuticals was included in the Russell indexes on July 1, 2025.Speculative2 reports
-
Tonix Pharmaceuticals announced a collaboration with Columbia University Medical School, and Seth Lederman was identified as the CEO of the company.Speculative1 report
-
Tonix Pharmaceuticals is conducting the OASIS study at the University of North Carolina, where Sina Bavari serves as Executive Vice President of Infectious Disease Research and Development.Speculative1 report
-
Tonix Pharmaceuticals conducted an OASIS study at the University of North Carolina.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Tonix Pharmaceuticals this week
News at the entities that move Tonix Pharmaceuticals most-
FDA StructuralPAVmed is facing the requirement of regulatory clearance for its company products, while also attracting institutional investment interest.Moves Tonix Pharmaceuticals
-
University of North Carolina StructuralCato held IT leadership positions at the UNC system and previously held leadership roles at Vassar College.Moves Tonix Pharmaceuticals
-
Medicare StructuralBrian Schatz seeks to reverse Medicaid cuts and advises moderating his political ambitions against vetoes.Moves Tonix Pharmaceuticals
-
Raymond James Financial Mentioned togetherMultiple financial firms, including Raymond James, Jefferies, and RBC, raised price targets for CM stock on October 24, 2026.Moves Tonix Pharmaceuticals
-
MarketBeat Mentioned togetherMarketBeat reported the consensus rating for Mammoth Energy Services, Inc. on October 24, 2026.Moves Tonix Pharmaceuticals
Connections
The 10 strongest of 32, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
The FDA formally regulated Tonix Pharmaceuticals, granting designations and final approval for its drug Tonmya.
-
Seth Lederman Structural
Seth Lederman serves as the Chief Executive Officer of Tonix Pharmaceuticals.
-
University of North Carolina Structural
Tonix Pharmaceuticals utilizes the University of North Carolina for clinical trials and drug development studies.
-
Medicare Structural
Tonix Pharmaceuticals secured a major managed payer agreement with Medicare.
-
International Association for the Study of Pain Shared context
Tonix Pharmaceuticals presented research at an International Association for the Study of Pain congress.
-
MarketBeat Mentioned together
MarketBeat provides analyst ratings and market coverage for Tonix Pharmaceuticals.
-
Raymond James Financial Mentioned together
Raymond James Financial provides analyst coverage that influences Tonix Pharmaceuticals' stock rating and price.
-
Frederick Shared context
Tonix Pharmaceuticals operates a research facility located in Frederick, Maryland.
Show all 10 connections
-
Valneva SE Mentioned together
Both Valneva SE and Tonix Pharmaceuticals are described as small-cap healthcare companies.
-
Ravalli County Shared context
Tonix Pharmaceuticals plans to establish a new facility in Ravalli County to support the local Montana economy.
History
Events by the month they beganOctober 2026
1 eventSeptember 2026
3 events- Tonix Pharmaceuticals CEO Seth Lederman purchased company stock in an insider transaction, while analyst coverage influences stock rating.
- Tonix Pharmaceuticals and Valneva are both identified as small-cap healthcare companies.
- Market comparison of small-cap biotechs involving Tonix Pharmaceuticals and Protalix Biotherapeutics.
June 2026
6 events- The FDA approved Tonix Pharmaceuticals' drug, Tonmya, for use in treating fibromyalgia.
- Tonix Medicines, Inc. became a commercial subsidiary of Tonix Pharmaceuticals on July 21, 2025.
- Tonix Pharmaceuticals was included in the Russell indexes on July 1, 2025.
- Tonix Pharmaceuticals announced a collaboration with Columbia University Medical School, and Seth Lederman was identified as the CEO of the company.
- Tonix Pharmaceuticals is conducting the OASIS study at the University of North Carolina, where Sina Bavari serves as Executive Vice President of Infectious Disease Research and Development.
- Tonix Pharmaceuticals conducted an OASIS study at the University of North Carolina.